International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

ABSTRACT: In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new "basket" clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized

SUBMITTER: Younes A 

PROVIDER: S-EPMC5834038 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature